Lowenthal Richard E 的 Form 4 申報
ARS Pharmaceuticals, Inc.（SPRY），2024/3/1 申報
- 申報編號
- 0001415889-24-006187
- 申報時間
- 2024/3/1
- 交易日
- 2024/2/29
- 申報延遲
- 1 天
- 10b5-1 計畫
- 有勾選
這份申報列了 3 筆非衍生性交易。公開市場賣出合計 $3.41 萬。交易後 1 天申報。
申報人
一份 Form 4 可以有好幾位申報人，例如本人與他控制的基金。各交易表上顯示的是第一位。
| 申報人 | 與公司的關係 |
|---|---|
| Lowenthal Richard ECIK 0001378550 | 董事、高階主管（總裁、執行長）、持股 10% 以上大股東 |
非衍生性證券（表 I）
普通股等股票的取得與處分，每一列是申報上的一筆。
附註與備註
本站收錄交易價格引用的附註、修正申報（Form 4/A）的全部附註，以及申報的備註。其他附註，例如間接持有的方式、交易計畫的細節，請看 SEC EDGAR 上的原文。
- F2
The weighted average sale price for the transaction reported was $9.0188, and the range of prices were between $9.00 and $9.10. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
表 I 有 1 筆交易的價格引用這則附註。
- F4
The weighted average sale price for the transaction reported was $9.0144, and the range of prices were between $9.00 and $9.10. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
表 I 有 1 筆交易的價格引用這則附註。
- F6
The weighted average sale price for the transaction reported was $9.0190, and the range of prices were between $9.00 and $9.10. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
表 I 有 1 筆交易的價格引用這則附註。